Literature DB >> 20493209

Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.

Bryan A Killinger1, Mary M Peet, Lisa E Baker.   

Abstract

Salvia divinorum is a small perennial shrub that has gained recent popularity among the drug-using subculture as a legal alternative to hallucinogens. Salvinorin A, the main active compound found in the S.divinorum plant, is an atypical hallucinogen with pharmacological selectivity at kappa opioid (KOP) receptor sites and is a unique non-nitrogenous neoclerodane diterpene which is structurally distinct from other opioid compounds. The novel structure of salvinorin A and its specific binding affinity to KOP receptors provide a unique opportunity to investigate neurochemical mechanisms of hallucination and hallucinogenic compounds. The current investigation assessed the substitution of salvinorin A in 16 male Sprague-Dawley rats trained to discriminate either the prototypical serotonergic hallucinogen, LSD (0.08mg/kg, S.C., n=8) or the dissociative anesthetic and glutamatergic hallucinogen, ketamine (8.0mg/kg, I.P., n=8) from vehicle under a FR 20 schedule of food-reinforced responding. Results indicated that neither LSD nor ketamine discrimination generalized to salvinorin A. These findings are consistent with the growing body of evidence that salvinorin A is pharmacologically distinct from other traditional hallucinogenic compounds. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493209     DOI: 10.1016/j.pbb.2010.05.014

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-01-10       Impact factor: 3.157

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

4.  Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Authors:  Veronica Serra; Liana Fattore; Maria Scherma; Roberto Collu; Maria Sabrina Spano; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 5.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

Review 6.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-01-20       Impact factor: 5.250

7.  Acute and post-acute behavioral and psychological effects of salvinorin A in humans.

Authors:  Peter H Addy
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

8.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

Review 9.  Animal models of serotonergic psychedelics.

Authors:  James B Hanks; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

Review 10.  Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.